Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals [Benzinga]
Thursday, February 19, 2026 1 min read
Key Takeaway: Enveric Biosciences has released new mechanistic data indicating that its lead drug candidate, EB-003, activates both Gq- and β-arrestin-mediated signaling through the 5-HT2A receptor. This drug is designed as a non-hallucinogenic neuroplastogen, aiming to facilitate streamlined treatment options, including the possibility of at-home administration.
Price reaction · baseline $2.24 (2026-02-18 close) · hit pre-market · 4 other ENVB headline(s) in the window, move may be shared
day 0 close
+8%
day 1
-0.9%
day 3
-1.8%
Market Sentiment Analysis
POSITIVE FACTORS
New data supports the effectiveness of EB-003.
EB-003 activates key signaling pathways in the brain.
Potential for at-home administration enhances treatment accessibility.
Full Press Release Details
Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration.
Full Article >>
Frequently Asked Questions
What is EB-003 developed for?
EB-003 is developed as a non-hallucinogenic neuroplastogen.
What receptors does EB-003 activate?
EB-003 activates both Gq- and β-arrestin-mediated signaling.
What are the potential benefits of EB-003?
It supports streamlined treatment paradigms, including at-home administration.